Interviewed about Deltex Medical Group’s new TrueVue system, Chief Exec Ewan Phillips talks about the product’s background. Specifically, he explains how the company is “changing the story” by adding best-in-class technologies to its high end oesophageal Doppler monitoring platform.
Ewan tells us “Deltex has always been a single technology company, selling a solution that is best described as imaging meets monitoring.”
There’s no doubting the evidence behind oesophageal Doppler monitoring, which has the potential to “halve the number of post-operative complications, once and for all.”
Barriers to its adoption however have always been that it requires learning and hard work to get the best from it. Also, it can only be used in certain patients, primarily those who are either asleep or sedated. Ewan says “so now we’ve added Impedance Cardiography, which is the best continuous monitoring solution for the awake patient. In combination with oesophageal Doppler and arterial pressure line inputs we now have all three major monitoring technologies in one place.”
